Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.
Costantino RicciElisa CapizziFrancesca GiunchiLaura CasolariFrancesco GelsominoKarim RihawiFilippo NataliVanina LiviRocco TrisoliniMichelangelo FiorentinoAndrea ArdizzoniPublished in: Therapeutic advances in medical oncology (2020)
Cytological smears can be used in routine clinical practice for PD-L1 assessment with a cut-off of 50%, expanding the potential pool of NSCLC patients as candidates for first-line single agent pembrolizumab therapy.
Keyphrases
- advanced non small cell lung cancer
- clinical practice
- epidermal growth factor receptor
- end stage renal disease
- ejection fraction
- small cell lung cancer
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- stem cells
- prognostic factors
- mesenchymal stem cells
- patient reported outcomes
- tyrosine kinase
- human health